Mail

Singapore markets close in 6 hours 37 minutes

Straits Times Index
3,180.29
-28.57(-0.89%)
Nikkei
31,297.13
-462.75(-1.46%)
Hang Seng
17,279.03
-530.63(-2.98%)
FTSE 100
7,510.72
-97.36(-1.28%)
Bitcoin USD
27,550.10
-420.21(-1.50%)
CMC Crypto 200
589.57
-13.97(-2.31%)

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed Price. Currency in USD

Add to watchlist

102.55

-0.40

(-0.39%)

At close: 04:01PM EDT

102.16

-0.39

(-0.38%)

After hours:

07:59PM EDT

Trade prices are not sourced from all markets

Previous close	102.95
Open	102.83
Bid	102.01 x 1400
Ask	102.55 x 800
Day's range	101.35 - 102.83
52-week range	87.00 - 119.65
Volume	7,079,722
Avg. volume	6,871,637

Market cap	260.223B
Beta (5Y monthly)	0.33
PE ratio (TTM)	83.37
EPS (TTM)	N/A
Earnings date	N/A
Forward dividend & yield	2.92 (2.84%)
Ex-dividend date	14 Sept 2023
1y target est	N/A

Press Releases

Business Wire
Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)
RAHWAY, N.J., September 28, 2023--Merck Receives Priority Review from FDA for Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with PAH
Business Wire
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
RAHWAY, N.J., September 22, 2023--Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of OS & PFS in Certain Patients With Previously Untreated la/m UC
Business Wire
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
RAHWAY, N.J., September 20, 2023--FDA Grants Priority Review to Merck’s Application for KEYTRUDA + Concurrent Chemoradiotherapy for Newly Diagnosed Locally Advanced Cervical Cancer